Autopsy report · NCT02811094

LUMIER² Study : LUpus Molecular Immunomonitoring to Evaluate the Risk of Relapse

“COVID situation”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 4 years 1 month before it stopped.
• 210 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Assistance Publique Hopitaux De Marseille

Sponsor type

University, hospital or other

Conditions

Systemic Lupus Erythematosus (SLE)

Interventions

polymerase chain reaction (PCR) technique of blood transcriptome analysis

Participants

210

Sites

1

Countries

France

Trials that died the same way

• MORphine Use in the Fascia Iliaca Compartment Block With UltraSound
  “COVID-19 crisis.” (80% match in meaning)
• Resting Energy Expenditure in Patients With OHS Treated With Long-term NIV
  “COVID pandemic” (78% match in meaning)
• Study of New Mutations in Cone Disorders
  “End of COVID” (77% match in meaning)
• Diversion Device With Breath Control
  “COVID and no plans to move forward” (76% match in meaning)
• Retrospective Study of COVID-19 Vaccines in Patients Undergoing Immunotherapy for Cancer.
  “end of the COVID outbreak” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.